Concurrent immunotherapy and re‐irradiation utilizing stereotactic body radiotherapy for recurrent high‐grade gliomas

Concurrent immunotherapy and re‐irradiation utilizing stereotactic body radiotherapy for recurrent high‐grade gliomas

Abstract Background Clinical trials evaluating immune checkpoint inhibition (ICI) in recurrent high‐grade gliomas (rHGG) report 7%–20% 6‐month progression‐free survival (PFS), while re‐irradiation demonstrates 28%–39% 6‐month PFS. Aims We evaluate outcomes of patients treated with ICI and concurrent...

Full description

Bibliographic Details
Main Authors: Sean S. Mahase, Michelle Roytman, Diana Roth O'Brien, Jana Ivanidze, Theodore H. Schwartz, Susan C. Pannullo, Rohan Ramakrishna, Rajiv S. Magge, Nicholas Williams, Howard A. Fine, Gloria Chia‐Yi Chiang, Jonathan P. S. Knisely
Format: Article
Language:English
Published: Wiley 2023-07-01
Series:Cancer Reports
Subjects:
immune checkpoint inhibitor
nivolumab
pembrolizumab
recurrent high‐grade glioma
stereotactic body radiotherapy
Online Access:https://doi.org/10.1002/cnr2.1788

Internet

https://doi.org/10.1002/cnr2.1788

Similar Items